UNITED
STATES SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
x
|
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2008
OR
o
|
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from
to
Commission file number 0-19195
AMERICAN
MEDICAL TECHNOLOGIES, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
|
38-2905258
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(I.R.S.
Employer Identification No.)
|
5655 Bear Lane, Corpus Christi, Texas
|
|
78405
|
(Address
of Principal Executive Offices)
|
|
(zip
code)
|
Registrants
Telephone Number, Including Area Code:
(361) 289-1145
Former Name, Former Address
and Former Fiscal Year, if Changed Since Last Report:
Not Applicable
Indicate by check mark
whether the registrant: (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes
x
No
o
Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See definitions
of large accelerated filer, accelerated filer, and smaller reporting
company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
o
|
|
Accelerated filer
o
|
|
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
x
|
(Do not check if a smaller reporting company)
|
|
|
Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes
o
No
x
Indicate the number of
shares outstanding of each of the issuers classes of common stock, as of the
latest practicable date.
Class of Common Stock
|
|
Outstanding at May 8, 2008
|
$0.04
par value
|
|
10,225,976
Shares
|
AMERICAN
MEDICAL TECHNOLOGIES, INC.
REPORT
ON FORM 10-Q
QUARTER
ENDED MARCH 31, 2008
TABLE
OF CONTENTS
2
PART I FINANCIAL
INFORMATION
ITEM 1. FINANCIAL
STATEMENTS
AMERICAN MEDICAL TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
|
|
March 31,
2008
|
|
December 31,
2007
|
|
|
|
(unaudited)
|
|
|
|
ASSETS
|
|
|
|
|
|
CURRENT ASSETS:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
20,771
|
|
$
|
20,369
|
|
Restricted certificate of deposit
|
|
314,692
|
|
313,950
|
|
Accounts receivable, less allowance of approximately $10,200 at
March 2008 and $16,500 at December 2007
|
|
204,516
|
|
272,113
|
|
Inventories, net
|
|
148,756
|
|
133,829
|
|
Prepaid expenses and other current assets
|
|
212,220
|
|
158,857
|
|
Total current assets
|
|
900,955
|
|
899,118
|
|
|
|
|
|
|
|
PROPERTY AND EQUIPMENT, net
|
|
79,829
|
|
89,912
|
|
|
|
|
|
|
|
INTANGIBLE ASSETS, net
|
|
808,391
|
|
849,030
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,789,175
|
|
$
|
1,838,060
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS
DEFICIT
|
|
|
|
|
|
CURRENT LIABILITIES:
|
|
|
|
|
|
|
|
|
|
|
|
Line of credit
|
|
$
|
590,000
|
|
$
|
500,000
|
|
Accounts payable
|
|
732,509
|
|
672,712
|
|
Compensation and employee benefits
|
|
42,074
|
|
48,236
|
|
Accrued restructuring costs
|
|
65,892
|
|
65,892
|
|
Warrants subject to registration rights
|
|
274,655
|
|
449,410
|
|
Other accrued liabilities
|
|
64,406
|
|
110,392
|
|
Total current liabilities
|
|
1,769,536
|
|
1,846,642
|
|
|
|
|
|
|
|
LONG-TERM LIABILITIES:
|
|
|
|
|
|
Deferred gain on sale of building
|
|
480,802
|
|
503,202
|
|
Total long-term liabilities
|
|
480,802
|
|
503,202
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES (Note 10)
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS DEFICIT
|
|
|
|
|
|
Preferred Stock, authorized 9,425,000 shares, none outstanding
|
|
|
|
|
|
Common stock, $.04 par value, authorized 100,000,000 shares; issued
and outstanding 10,225,976 and 10,117,274 respectively
|
|
409,039
|
|
404,691
|
|
Additional paid-in capital
|
|
43,830,882
|
|
43,790,539
|
|
Accumulated deficit
|
|
(44,701,084
|
)
|
(44,707,014
|
)
|
Total stockholders deficit
|
|
(461,163
|
)
|
(511,784
|
)
|
Total liabilities and stockholders deficit
|
|
$
|
1,789,175
|
|
$
|
1,838,060
|
|
See accompanying notes to consolidated financial statements.
3
AMERICAN MEDICAL TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
|
Three Months
Ended March 31,
|
|
|
|
2008
|
|
2007
|
|
|
|
|
|
|
|
REVENUES
|
|
$
|
636,295
|
|
$
|
855,118
|
|
|
|
|
|
|
|
ROYALTIES
|
|
3,614
|
|
6,063
|
|
|
|
639,909
|
|
861,181
|
|
COST OF SALES
|
|
193,480
|
|
308,909
|
|
Gross profit
|
|
446,429
|
|
552,272
|
|
|
|
|
|
|
|
COST AND EXPENSES:
|
|
|
|
|
|
Selling, general and administration
|
|
637,288
|
|
770,596
|
|
Research and development
|
|
|
|
9,212
|
|
Loss from operations
|
|
(190,859
|
)
|
(227,536
|
)
|
|
|
|
|
|
|
OTHER INCOME (EXPENSES):
|
|
|
|
|
|
Net realized and unrealized gains on investments
|
|
742
|
|
800
|
|
Gain on sale of machinery
|
|
|
|
76,101
|
|
Other income
|
|
29,369
|
|
42,893
|
|
Change in fair value of warrant
|
|
174,755
|
|
(574,974
|
)
|
Interest income
|
|
|
|
1,664
|
|
Interest expense
|
|
(9,421
|
)
|
(11,666
|
)
|
Total other income(expenses)
|
|
195,445
|
|
(465,182
|
)
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
4,586
|
|
$
|
(692,718
|
)
|
|
|
|
|
|
|
Basic and diluted earnings per common share
|
|
$
|
0.00
|
|
$
|
(0.08
|
)
|
|
|
|
|
|
|
Weighted number of shares issued
|
|
10,166,250
|
|
8,189,306
|
|
See accompanying notes to consolidated financial statements.
4
AMERICAN MEDICAL TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2007
|
|
OPERATING ACTIVITIES:
|
|
|
|
|
|
Net income (loss)
|
|
$
|
4,586
|
|
$
|
(692,718
|
)
|
Adjustments to reconcile net income (loss) to net cash used in
operating activities:
|
|
|
|
|
|
Depreciation
|
|
11,154
|
|
12,941
|
|
Amortization
|
|
40,639
|
|
27,718
|
|
Provision for slow-moving inventory
|
|
(37,408
|
)
|
19,326
|
|
Provision of doubtful accounts
|
|
(6,312
|
)
|
13,219
|
|
Gain on sale of machinery
|
|
|
|
(76,101
|
)
|
Gain recognized on sale of building
|
|
(38,219
|
)
|
(38,218
|
)
|
Net realized and unrealized gains on investments
|
|
(742
|
)
|
800
|
|
Expense related to option grants
|
|
18,603
|
|
38,067
|
|
Change in fair value of warrant
|
|
(174,755
|
)
|
574,974
|
|
Expense related to stock compensation
|
|
26,088
|
|
|
|
Total other operating activities
|
|
(160,952
|
)
|
572,726
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
Accounts receivable
|
|
73,908
|
|
(2,138
|
)
|
Inventories
|
|
22,481
|
|
(36,263
|
)
|
Prepaid expenses and other current assets
|
|
(53,363
|
)
|
(80,769
|
)
|
Accounts payable
|
|
59,798
|
|
133,564
|
|
Compensation and employee benefits
|
|
(6,162
|
)
|
(63,686
|
)
|
Other accrued liabilities
|
|
(45,986
|
)
|
30,394
|
|
Deferred income
|
|
15,819
|
|
|
|
Net cash used in operating activities
|
|
(89,871
|
)
|
(138,890
|
)
|
|
|
|
|
|
|
INVESTING ACTIVITIES:
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
(1,071
|
)
|
(4,768
|
)
|
Proceeds from sale of machinery
|
|
|
|
76,300
|
|
Sales and maturities of government securities
|
|
|
|
51,161
|
|
Net cash (used) provided by investing activities
|
|
(1,071
|
)
|
122,693
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES:
|
|
|
|
|
|
Proceeds from line of credit
|
|
90,000
|
|
120,000
|
|
Net cash provided by financing activities
|
|
90,000
|
|
120,000
|
|
|
|
|
|
|
|
Net increase(decrease) in cash and cash equivalents
|
|
(942
|
)
|
103,803
|
|
Effect of exchange rates on cash
|
|
1,344
|
|
|
|
Increase in cash and cash equivalents
|
|
402
|
|
103,803
|
|
|
|
|
|
|
|
CASH and cash equivalents, at beginning of
period
|
|
20,369
|
|
65,821
|
|
|
|
|
|
|
|
CASH and cash equivalents, at end of period
|
|
$
|
20,771
|
|
$
|
169,624
|
|
See accompanying notes to consolidated financial statements.
5
American Medical Technologies, Inc.
Notes to Interim
Consolidated Financial Statements
1.
Basis of Presentation and Other Accounting Information
Basis of Presentation
The
accompanying unaudited condensed consolidated financial statements of American
Medical Technologies, Inc. (the Company or AMT) have been prepared by
management in accordance with accounting principles generally accepted in the
United States of America for interim financial information and with the
instructions to Form 10-Q and Article 8 of Regulation S-X and
with the presumption that the Company will continue as a going concern.
Accordingly, they do not include all information and footnotes required by
generally accepted accounting principles for complete financial statements. In
the opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been included.
The
results of operations for the three months ended March 31, 2008 are not
necessarily indicative of the results to be expected for the year ending December 31,
2008. The accompanying unaudited
condensed consolidated financial statements should be read with the
annual consolidated financial statements and notes contained in the Companys
Annual Report on Form 10-KSB for the fiscal year ended December 31,
2007.
Liquidity
The
Companys financial statements are prepared using accounting principles
generally accepted in the United States of America applicable to a going
concern, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business. The Company incurred net
income/(loss) attributable to common shareholders of $4,586 and ($692,718) for
the three month periods ended March 31, 2008 and March 31, 2007, respectively.
The Companys recurring losses from operations and the Companys total
liabilities exceeding its total assets raise substantial doubt as to the
Companys ability to continue as a going concern. The Company believes
that the increases in revenue and gross margin due to the addition of new
product line representations and additional funds available from the line of
credit will alleviate the doubt about the Companys ability to continue as a
going concern; however, no assurances can be made.
Inventories
Inventories
consist of the following:
|
|
March 31
2008
|
|
December 31
2007
|
|
Finished goods
|
|
$
|
70,061
|
|
$
|
55,273
|
|
Raw materials, parts and supplies
|
|
78,695
|
|
78,556
|
|
Total inventory net of reserve
|
|
$
|
148,756
|
|
$
|
133,829
|
|
The
Companys reserve for slow moving inventory is evaluated periodically based on
its current and projected sales and usage. The inventory reserve calculation
assumes that any parts on hand exceeding three years of projected usage are
subject to complete valuation allowance.
The
Company recorded a $37,408 decrease to the reserve for the three months ended March 31,
2008 and a $19,326 increase to the reserve for the three months ended March 31,
2007. The Companys reserve for slow
moving inventory was approximately $967,000 at March 31, 2008 and
$1,505,000 at March 31, 2007. The
valuation allowance could change materially, either up or down, if actual parts
usage in future years is
6
materially
different than the usage projected at March 31, 2008; however, the new
cost basis cannot subsequently be marked up based on changes in underlying
facts and circumstances.
Earnings Per Share
- The following table sets forth the computation for basic and diluted
earnings per share:
|
|
Three Months Ended
March 31
|
|
|
|
2008
|
|
2007
|
|
|
|
|
|
|
|
Net income(loss) available to common
stockholders
|
|
$
|
4,586
|
|
$
|
(692,718
|
)
|
|
|
|
|
|
|
Numerator for basic and diluted earnings
per share
|
|
4,586
|
|
(692,718
|
)
|
|
|
|
|
|
|
Denominator for basic earnings per share
weighted average shares
|
|
10,166,250
|
|
8,189,306
|
|
|
|
|
|
|
|
Dilutive potential common shares:
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted earnings per share
adjusted weighted-average shares after assuming conversion
|
|
10,166,250
|
|
8,189,306
|
|
|
|
|
|
|
|
Basic and diluted earnings per common share
available to common stockholders
|
|
$
|
0.00
|
|
$
|
(0.08
|
)
|
Potentially dilutive
securities include options and warrants.
As of March 31, 2008 there were no potentially dilutive
securities. As of March 31, 2007
there were approximately 654,000 shares issuable in connection with these
potentially dilutive securities. The
potentially dilutive securities were excluded from the computations of diluted
net loss per share for March 31, 2007 because their effect would have been
antidilutive. The computation of diluted
earnings per share for March 31, 2007 excludes the effect of assuming the
conversion of the 400,000 shares of Preferred Stock which were convertible for
two and one-half shares of common stock because the effect would have been
antidilutive.
Fair Value Measurement
We adopted SFAS 157 effective January 1, 2008 for financial assets
and liabilities measured on a recurring basis.
SFAS 157 applies to all financial assets and financial liabilities that
are being measured and reported on a fair value basis. In February 2008, the FASB issues FSP
157-2, which delayed the effective date of SFAS 157 to fiscal years beginning
after November 15, 2008 for nonfinancial assets and liabilities. Fair value, as defined in SFAS 157, is the
price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement
date. SFAS 157 affects the Company in
the fair value measurement of the commodity and interest rate derivative
positions which must be classified in one of the following categories:
Level 1 Inputs
These
inputs come from quoted prices (unadjusted) in active markets for identical
assets or liabilities.
Level 2 Inputs
These
inputs are other than quoted prices that are observable, for an asset or
liability. This includes: quoted prices for similar assets or
liabilities in active markets; quoted prices for identical or similar assets or
liabilities in markets that are not active; inputs other than quoted prices
that are observable for the asset
7
or
liability; and inputs that are derived principally from our corroborated by
observable market data by correlation or other means.
Level 3 Inputs
These
are unobservable inputs for the asset or liability which require the Companys
own assumptions.
As
required by SFAS 157, financial assets and liabilities are classified based on
the lowest level of input that is significant to the fair value
measurement. Our assessment of the
significance of a particular input to the fair value measurement requires
judgment, and may affect the valuation of the fair value of assets and
liabilities and their placement within the fair value hierarchy levels
The
following table summarizes the valuation of our financial instruments by SFAS
157 input levels as of March 31, 2008:
|
|
Fair Value Measurement
|
|
Description (Liabilities)
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Current liabilities
|
|
$
|
|
|
$
|
274,655
|
|
$
|
|
|
$
|
274,655
|
|
Total
|
|
$
|
|
|
$
|
274,655
|
|
$
|
|
|
$
|
274,655
|
|
2.
Employee Stock Options
The
Company currently sponsors a stock based compensation plan as described below.
Effective January 1, 2006, the Company adopted the provisions of Statement
of Financial Accounting Standards (SFAS) No. 123 (Revised), Share-Based
Payment. In accordance with the provisions of SFAS No. 123(R),
stock based compensation is measured at the grant date based on the value of
the awards and is recognized as expense over the requisite service period
(usually the vesting period). The fair values of the stock awards recognized
under SFAS No. 123(R) are determined based on each separately vesting
portion of the awards, however, the total compensation expense is recognized on
a straight-line basis over the vesting period. The Company has a policy of
issuing new shares for stock option exercises.
In
accordance with the provisions of SFAS No. 123(R), there was $18,603 in
stock based compensation expense recorded in the three months ended March 31,
2008.
Employee Stock Option Plan
In
May 2005, the Company adopted the 2005 Stock Option Plan (the Plan) for
employees, officers, directors, consultants and other key personnel. When the Plan was implemented there were
options to purchase 1,000,000 shares common stock available to be be
granted under the Plan. In the first
quarter of 2007, the Company increased the number of options to purchase to
2,000,000 shares of common stock.
The
Company granted 400,000 share options in June 2006 under the Plan. The share options became exercisable at a
rate of 100,000 per year beginning in September 2006. The fair value of the options issued was
estimated at the date of the grant using the Black-Scholes option pricing model
with the following assumptions: risk
free interest rate of 5.14%; dividend yield of 0%, volatility factors of 238%,
the expected market price over the estimated life of the option of 6.25
years. In January 2007, the
unvested portion of this grant was cancelled.
The calculated fair value of the portion of the option grant that
remained was $26,813. The Company
recognized the full expense in 2006.
The
Company granted 100,000 share options in January 2007 under the Plan. The share options became exercisable upon the
grant date. The fair value of the
options issued was estimated at the date of the grant
8
using
the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 4.68%; dividend
yield of 0%, volatility factors of 241%, the expected market price over the
estimated life of the option of 5.5 years.
The calculated fair value of the option grant was $19,916. The Company recognized the expense in the
first quarter 2007.
Additionally,
the Company granted 870,000 share options in January 2007 under the
Plan. The share options will become
exercisable at a rate of 290,000 per year beginning in December 2007. The fair value of the options issued was
estimated at the date of the grant using the Black-Scholes pricing model with
the following assumptions: risk free
interest rate of 4.68%, dividend yield of 0%, volatility factors of 243%, the
expected market price over the estimated life of the option of 6 years. The calculated fair value of the option
grants was $173,567. The Company is
recognizing the expense of over the three year vesting period of the options.
The
Company granted 11,000 share options in February 2007 under the Plan. The share options will become exercisable in February 2008. The fair value of the options issued was
estimated at the date of the grant using the Black-Scholes option pricing model
with the following assumptions: risk
free interest rate 4.77%, dividend yield of 0%, volatility factors of 234% the
expected market price over the estimated life of the option of 5.5 years. The calculated fair value of the option
grants was $2,188. The Company is
recognizing the expense over the vesting period of the options.
The
Company granted 60,000 share options in March 2007 under the Plan. The share options will become exercisable at
a rate of 30,000 per year beginning in March 2008. The fair value of the options issued was
estimated at the date of the grant using the Black-Scholes pricing model with
the following assumptions: risk free
interest rate of 4.5%, dividend yield 0%, volatility factors of 247%, the
expected market price over the estimated life of the options of 5.75
years. The calculated fair value of the
option grants was $25,132. The Company
is recognizing the expense over the two year vesting period of the options.
As
of March 31, 2008 there was $108,824 of total unrecognized compensation
cost related to nonvested share based compensation arrangements granted under
the Plan.
The
Companys nonvested share options as of December 31, 2007 and changes
during the three months ended March 31, 2008, is summarized as follows:
Nonvested Shares
|
|
Shares
|
|
Weighted-Average
Grant-Date
Fair Value
|
|
Nonvested at December 31, 2007
|
|
688,000
|
|
$
|
0.22
|
|
Granted
|
|
|
|
$
|
|
|
Vested
|
|
(77,000
|
)
|
$
|
0.29
|
|
Forfeited
|
|
(1,000
|
)
|
$
|
0.20
|
|
Nonvested at March 31, 2008
|
|
610,000
|
|
$
|
0.21
|
|
Employee
stock option activity is summarized as follows:
|
|
Number
of shares
|
|
Weighted-
Average
Exercise
Price
|
|
Weighted
Average
Grant Date
Fair Value
|
|
Weighted
Average
Remaining
Contractual
Term (Years)
|
|
Aggregate
Intrinsic
Value
|
|
Outstanding at December 31, 2007
|
|
1,142,680
|
|
$
|
0.22
|
|
|
|
8.95
|
|
|
|
Exercisable at December 31,2007
|
|
454,680
|
|
0.23
|
|
|
|
8.83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
|
|
|
|
|
|
|
|
|
Options exercised
|
|
|
|
|
|
|
|
|
|
|
|
Options canceled
|
|
(1,000
|
)
|
0.20
|
|
200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2008
|
|
1,141,680
|
|
0.22
|
|
|
|
8.70
|
|
|
|
Exercisable at March 31, 2008
|
|
531,680
|
|
0.24
|
|
|
|
8.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
3.
2007 Equity Incentive Plan
In
July 2007, the Company adopted the 2007 Equity Incentive Plan (Equity
Plan). The Equity Plan provides for the
granting of Nonqualified Stock Options, Incentive Stock Options, Stock
Appreciation Rights (or SARs), Restricted Stock, Performance Units and
Performance Shares to employees, consultants and directors. The purpose of the Equity Plan is to promote
the success and to enhance the value of
the Company by aligning the interest of Participants with those of the Companys
shareholders, to provide flexibility to the Company in its ability to motivate,
attract, and retain the services of outstanding individuals, upon whose
judgment, interest, and special effort the success of the Company is largely
dependent. When the Equity Plan was
implemented there were 1,000,000 common shares available to be granted under
the Equity Plan. In the three months
ended March 31, 2008, a total of 108,702 performance unit shares had been
granted under the Equity Plan to legal consultants of the Company. The $26,088 expense is included in other
professional fees.
4.
Segment Reporting
SFAS
No. 131, Disclosures about Segments of an Enterprise and Related
Information, established standards for reporting information about operating
segments in annual financial statements and required selected information about
operating segments in interim financial reports issued to stockholders.
It also established standards for related disclosures about products and
services, and geographic areas. Operating segments are defined as
components of the enterprise about which separate financial information is
available that is evaluated regularly by the chief operating decision maker, or
decision making group, in deciding how to allocate resources and in assessing
performance.
The
Company develops, manufactures, markets and sells high technology dental
products, such as air abrasive equipment and curing lights as well as, tooth
whitening products. AMT markets its dental products through dealers
and independent distributors to general dental practitioners and certain
other dental specialists. Internationally, the Company continues to sell
its products through international distributor networks. AMT presently
markets its industrial products through independent distributors. The
reportable segments are reviewed and managed separately because selling
techniques and market environments differ from selling domestically versus
selling through international distributor networks. The remaining
revenues of the Company, which are reported as Other, represent royalty
income.
The
accounting policies of the business segments are consistent with those used in
prior years.
10
|
|
Three Months Ended
March 31
|
|
|
|
2008
|
|
2007
|
|
Revenues
|
|
|
|
|
|
Domestic
|
|
$
|
413,576
|
|
$
|
557,830
|
|
International
|
|
222,719
|
|
297,288
|
|
|
|
$
|
636,295
|
|
$
|
855,118
|
|
|
|
|
|
|
|
Reconciliation of revenues:
|
|
|
|
|
|
Total segment revenues
|
|
$
|
636,295
|
|
$
|
855,118
|
|
Other
|
|
3,614
|
|
6,063
|
|
Total revenues
|
|
$
|
639,909
|
|
$
|
861,181
|
|
|
|
|
|
|
|
Operational earnings:
|
|
|
|
|
|
Domestic
|
|
$
|
226,602
|
|
$
|
237,665
|
|
International
|
|
26,356
|
|
103,330
|
|
|
|
$
|
252,958
|
|
$
|
340,995
|
|
|
|
|
|
|
|
Reconciliation of operational earnings to
loss from operation:
|
|
|
|
|
|
Total segment operational earnings
|
|
$
|
252,958
|
|
$
|
340,995
|
|
Other operational earnings
|
|
3,614
|
|
6,063
|
|
Research & development Expense
|
|
|
|
(9,212
|
)
|
Administrative expenses
|
|
(447,431
|
)
|
(565,382
|
)
|
Loss from operations
|
|
$
|
(190,859
|
)
|
$
|
(227,536
|
)
|
|
|
|
|
|
|
International revenues by country:
|
|
|
|
|
|
Japan
|
|
$
|
23,433
|
|
$
|
12,773
|
|
England
|
|
3,401
|
|
13,112
|
|
The Netherlands
|
|
12,006
|
|
65,758
|
|
Singapore
|
|
13,715
|
|
36,735
|
|
Switzerland
|
|
|
|
16,900
|
|
Argentina
|
|
1,492
|
|
11,882
|
|
Germany
|
|
44,155
|
|
3,546
|
|
Korea
|
|
15,060
|
|
3,072
|
|
Lebanon
|
|
20,938
|
|
|
|
Costa Rica
|
|
3,330
|
|
13,335
|
|
Peru
|
|
8,235
|
|
6,319
|
|
Canada
|
|
29,242
|
|
65,758
|
|
Other
|
|
47,712
|
|
48,098
|
|
|
|
$
|
222,719
|
|
$
|
297,288
|
|
|
|
|
|
|
|
|
|
March 31,
2008
|
|
December 31,
2008
|
|
Long lived assets
|
|
|
|
|
|
Domestic
|
|
$
|
79,829
|
|
$
|
89,912
|
|
International
|
|
|
|
|
|
|
|
$
|
79,829
|
|
$
|
89,912
|
|
11
5.
Comprehensive Income
Total
comprehensive income, net of the related estimated tax, was $5,930 for the
three months ended March 31, 2008.
The components of other comprehensive loss for 2008 are net loss and
foreign currency translation.
6.
Line of Credit
On
December 21, 2006, the Company entered into a secured line of credit
agreement with Texas State Bank. The funds available under the line of
credit were $600,000. The Company invested $300,000 with funds drawn
against the line of credit in a Certificate of Deposit with a term of one year
as collateral for the loan. Interest on the line of credit is set at the
prime rate plus 1%. The interest rate on the line of credit was 6.25% as
of March 31,2008. The principal on the loan was payable in one
payment on December 20, 2007, with interest on the outstanding amount
payable monthly. The Company borrowed an additional $100,000 against the
line of credit in December 2006. In February 2007, Texas State
Bank increased the line of credit to $800,000 using the Companys accounts
receivable and inventory as additional collateral. The terms of the
original line of credit remained the same with the exception of the payment
date of the line being extended to February 2008. In January 2008,
the Company renewed the secured line of credit agreement. The terms of the
original line of credit remained the same with the exception of the payment
date which was extended to January 2009.
The balance outstanding was $590,000 at March 31, 2008.
7.
Income Taxes
FIN
48 - In June 2006, FASB Interpretation (FIN) No. 48, Accounting for
Uncertainty in Income Taxes, an interpretation of FASB Statement 109 Accounting
for Income Taxes, was issued. FIN No. 48 describes accounting for
uncertainty in income taxes, and includes a recognition threshold and
measurement attribute for recognizing the effect of a tax position taken or
expected to be taken in a tax return. FIN No. 48 is effective for
fiscal years beginning after December 15, 2006. The Company adopted FIN No. 48 on January 1,
2007, and the initial adoption of this Statement had no material impact on the
Companys financial position, results of operations or cash flows. The tax years still open for examination by
Federal and major state agencies as of March 31, 2008 are 2003 2006.
8.
Related Party Transactions
Roger Dartt
In consideration of his continued work during
the three month period ended March 31, 2007, the Company agreed to issue
200,000 shares of common stock to Mr. Dartt. The common stock was issued in August 2007. The Company recorded an estimated expense of
$78,000 for the stock issuance in the first quarter of 2007. The Company issued 200,000 restricted shares
of common stock to Mr. Dartt and made an adjustment to the actual expense
of $60,000 in September 2007.
9.
Other Events
Detailer Agreement DentNCo
On March 20,
2008 the Company entered into a three year Authorized Detailer Agreement with
DentNCo, a French company, under which the Company became an authorized broker
and detailer of DentNCos Flexiwhite Tooth Whitening Light and related
accessories. The Company was appointed
as an exclusive authorized detailer in certain international markets. In consideration of the Companys efforts to
develop and retain an international dealer network, DentNCo will pay the
Company monthly commission for all products sold in the AMT managed territory
during the agreement period.
License Agreement Sheervision, Inc.
On October 24,
2007, the Company entered into a one year Authorized Detailer Agreement with
Sheervision, Inc. (Sheervision), a Delaware corporation, under which the
Company became an authorized broker and detailer of Sheervisions Firefly
Infinity LED Headlight and all related accessories. The agreement will be renewed for an
additional one or two year
12
period
in 2008. The Company was appointed as an
exclusive authorized detailer in certain international markets and as a
non-exclusive authorized detailer in Sheervisions retained territory,
excluding the United States of America.
In consideration of the Companys efforts to develop and retain an
international dealer network, Sheervision will pay the Company a monthly
management fee during the first four months of the agreement and a commission
for all products sold in the AMT managed territory during the agreement period.
License Agreement CrownBeav LLC DirectCrown product
line
On April 1,
2007, the Company entered into a License Agreement with CrownBeav LLC, an
Oregon limited liability company, under which the Company became the
nonexclusive distributor for the United States and Canada and the exclusive
distributor for the rest of the world of its DirectCrown brand of temporary
crown and bridge material. The license agreement is for a term of ten
years with automatic renewals for additional five year terms, contains minimum
requirements for sale of the products by the Company, and may be terminated (i) for
cause upon 60 days notice, (ii) upon the Companys failure to comply with
applicable securities laws, (iii) upon the occurrence of certain other
customary events of default. In full consideration, the Company granted
to CrownBeav a five year option to purchase (the Option) 1,000,000 shares of
common stock at $0.20 per share. The shares subject to the Option will
vest two years from the Effective Date of the agreement. The option
agreement includes a guaranteed trading price of $0.40 per share for the 30-day
period prior to vesting. Additional option shares will be granted for the
difference if the market price of the shares is below $0.40 during the 30-day
period.
The
Black-Scholes option pricing model was used to determine the fair value of the
options issued to CrownBeav with the following assumptions: risk free
interest rate of 4.54%; dividend yield of 0%; volatility factors of 139%, the
expected market price of the Companys common shares over the estimated life of
the option of 3.5 years. The resulting fair value of the call option was
$341,726. The option grant vests on April 1, 2009. The option
agreement includes a guaranteed trading price of $0.40 per share for the 30-day
period prior to vesting. Additional options will be granted for the
difference if the market price is below $0.40 during the 30-day period.
The Black-Scholes option pricing model was used to determine the fair value of
the option guarantee issued to CrownBeav with the following assumptions:
risk free interest rate of 4.60%; dividend yield of 0%; volatility factors of
100%, the expected market price of the Companys common shares over the
guarantee period of 2 years. The resulting fair value of the put option
was $185,000. The $526,726 fair market value of the option (combination
of call and put) was capitalized as an intangible asset and is being recognized
as a licensing fee over the 10 year period of the license.
10.
Subsequent Event
On
May 9, 2008, the building at 5655 Bear Lane, Corpus Christi, Texas was
sold by Bear Street Associates (Bear Street, formerly Supulveda Group) and
the lease between Bear Street and AMT was terminated. In consideration of the early lease
termination, AMT entered into an agreement to pay $250,000 over a 10 month
period beginning in June 2008. The
Company expects to negotiate a lease for a portion of the building with the new
owner and to continue operations at this facility.
ITEM 2.
MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward Looking Statements
The
Company makes forward-looking statements in this report and may make such
statements in future filings with the Securities and Exchange Commission.
The Company may also make forward-looking statements in its press releases or
other public shareholder communications. The Companys forward-looking
statements are subject to risks and uncertainties and include information about
its expectations and possible or assumed future results of operations.
When the Company uses any of the words believes, expects, anticipates, estimates
or similar expressions, it is making forward-looking statements.
13
To
the extent available, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995 for all of its forward-looking statements. While the
Company believes that its forward-looking statements are reasonable, you should
not place undue reliance on any such forward-looking statements, which speak
only as of the date made. Because these forward-looking statements are
based on estimates and assumptions that are subject to significant business,
economic and competitive uncertainties, many of which are beyond the Companys
control or are subject to change, actual results could be materially
different. Factors that might cause such a difference include, without
limitation, the following: the Companys inability to generate sufficient
cash flow to meet its current liabilities, the inability of the Company to find
suitable new acquisitions or the expense or difficulty of integrating such
acquisitions with current Company operations, adverse results in any of the
Companys material lawsuits, the possible failure of revenues to offset
additional costs associated with its new business model, the potential lack of
product acceptance, the Companys potential inability to introduce new products
to the market, the potential failure of customers to meet purchase commitments,
the potential loss of customer relationships, the potential failure to receive
or maintain necessary regulatory approvals, the extent to which competition may
negatively affect prices and sales volumes or necessitate increased sales
expenses, the failure of negotiations to establish original equipment
manufacturer agreements or strategic alliances and the other risks and
uncertainties set forth in this report.
Other
factors not currently anticipated by management may also materially and
adversely affect the Companys results of operations. Except as required
by applicable law, the Company does not undertake any obligation to publicly
release any revisions which may be made to any forward-looking statements to
reflect events or circumstances occurring after the date of this report.
Critical Accounting Policies
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires the Company to make estimates
and assumptions that affect amounts reported in the accompanying consolidated
financial statements and related footnotes. These estimates and assumptions are
evaluated on an on-going basis based on historical developments, market
conditions, industry trends and other information the Company believes to be
reasonable under the circumstances. There can be no
assurance that actual results will
conform to the Companys estimates and assumptions, and that reported
results of operations will not be materially adversely affected by the need to
make accounting adjustments to reflect changes in these estimates and
assumptions from time to time. The policies the Company believes to be the most
sensitive to estimates and judgments are described in Item 7 of the Companys
2008 Annual Report on Form 10-KSB.
Results of Operations
The
Company had revenues of $636,295 for the three months ended March 31, 2008
compared to $855,118 for the same period in 2007, a decrease of 26%. For the three month period, domestic revenues
decreased 26%, while international revenues decreased 25%. The decrease in revenues is primarily
attributable to a $130,000 decrease in sales of the Spectrum product line due to
a major distributor placing a large order in the fourth quarter 2007 in
anticipation of a January 2008 price increase and a $60,400 decrease in
the sales of parts and repairs due to the historical decrease in sales of
equipment. Additionally, the three month period ended March 31, 2007
included a $44,000 sale of inventory previously included in the Companys
inventory reserve. These decreases were
partially offset by $33,400 in commission earned from the DirectCrown product
line added in April 2007. The
Company expects the continued decrease in revenues for parts and repairs and
increases in the revenues for Spectrum, DirectCrown and other recently added
brokered product lines.
Additionally,
royalties decreased $2,449 for the three months ended March 31, 2008.
Gross
profit as a percentage of revenues was 70% for the three month period ended March 31,
2008 compared to 65% for the same period in 2007. The increase in gross profit is primarily
attributable the sale or use of inventory previously included in the Companys
inventory reserve which resulted in a $37,400
14
decrease
in the inventory valuation allowance.
Additionally, a portion of the increase in gross profit is related to
the addition of the DirectCrown product line revenues received as commissions.
Selling,
general and administrative expenses were $637,288 for the three month period
ended March 31, 2008 compared to $770,596 for the same period in 2007, a
decrease of 17%. The decrease is
primarily attributable to a $112,700 decrease in payroll expense due to $77,000
in expenses related to a stock grant in 2007; a $9,200 decrease in show
expenses as a result of AMTs distributors representing the Companys product
lines at shows on the Companys behalf; a $11,300 decrease in other professional
fees as a result of litigation settled in 2007 and a $17,600 decrease in other
expenses. These decreases were partially
offset by a $12,800 increase in marketing expense and $12,500 in insurance
expense. The Company is diligently
working to continue to reduce selling, general and administrative expenses.
There
were no research and development expenses in the three month period ended March 31,
2008 compared to $9,212 for the same period on 2007. The Company does not anticipate the
development of new product lines for manufacturing.
Other
income was $29,369 for the three month period ended March 31, 2008
compared to $42,895 for the same period in 2007. The decrease in other income is primarily
attributable to a decrease in fees received for consulting services. The Company does not expect additional fees
for consulting services for the remainder of 2008.
Liquidity and Capital Resources
The
Companys operating activities used $89,871 for the three month period ended March 31,
2008.
The
Companys investing activities used $1,071 for the three month period ended March 31,
2008.
The
Companys financing activities provided $90,000 for the three month period
ended March 31, 2008 in funds received from the Companys line of credit
with Texas State Bank.
On
December 21, 2006, the Company entered into a secured line of credit
agreement with Texas State Bank. The funds available under the line of
credit were $600,000. The Company invested $300,000 with funds drawn
against the line of credit in a Certificate of Deposit with a term of one year
as collateral for the loan. Interest on the line of credit is set at the
prime rate plus 1%. The interest rate on the line of credit was 6.25% as
of March 31, 2008. The principal on the loan was payable in one
payment on December 20, 2007, with interest on the outstanding amount
payable monthly. The Company borrowed an additional $100,000 against the
line of credit in December 2006. In February 2007, Texas State
Bank increased the line of credit to $800,000 using the Companys accounts
receivable and inventory as collateral. In January 2008, the Company
renewed the secured line of credit agreement. The terms of the original
line of credit remained the same with the exception of the payment date which
was extended to January 2009.
On
April 11, 2006, the Company entered into a licensing agreement with Discus
Dental Holdings, Inc. (Discus) and its wholly owned subsidiary, Spectrum
Dental, Inc. (Spectrum Dental), a leading provider of professional tooth
whitening products under the brand names of Contrastpm, Contrastpmplus and Contrastam,
under which AMT became the exclusive distributor of the Spectrum Dental product
line, which provided approximately $933,000 in additional revenue in
2006. The Sepulveda Group, LLC is affiliated with Discus. In full payment for
the license, the Company issued Discus a warrant to purchase 2,500,000 shares
of common stock at $0.20 per share.
The
fair value of the warrants issued to Discus is estimated at the end of each
period using the Black-Scholes option pricing model with the following
assumptions used on March 31, 2008: risk free interest rate of
2.46%; dividend yield of 0%; volatility factors of 258%, the expected market
price of the Companys common shares over the estimated life of the warrant of
6.5 years. The calculated fair value of the warrant as of December 31,
2007 was $449,412. The calculated fair value of the warrant on the grant
date was $549,530 which the Company capitalized as an intangible asset and is
recognizing as a licensing fee over the vesting period of five years.
15
On
April 1, 2007, the Company entered into a License Agreement with CrownBeav
LLC, an Oregon limited liability company, under which the Company became the
nonexclusive distributor for the United States and Canada and the exclusive
distributor for the rest of the world of its DirectCrown brand of temporary
crown and bridge material. The license agreement is for a term of ten
years with automatic renewals for additional five year terms, contains minimum
requirements for sale of the products by the Company, and may be terminated (i) for
cause upon 60 days notice, (ii) upon the Companys failure to comply with
applicable securities laws, (iii) upon the occurrence of certain other
customary events of default. In full consideration, the Company granted
to CrownBeav a five year option to purchase (the Option) 1,000,000 shares of
common stock at $0.20 per share. The shares subject to the Option will
vest two years from the Effective Date of the agreement. The option
agreement includes a guaranteed trading price of $0.40 per share for the 30-day
period prior to vesting. Additional option shares will be granted for the
difference if the market price of the shares is below $0.40 during the 30-day
period.
The
Black-Scholes option pricing model was used to determine the fair value of the
options issued to CrownBeav with the following assumptions: risk free
interest rate of 4.54%; dividend yield of 0%; volatility factors of 139%, the
expected market price of the Companys common shares over the estimated life of
the option of 3.5 years. The resulting fair value of the call option was
$341,726. The option grant vests on April 1, 2009. The option
agreement includes a guaranteed trading price of $0.40 per share for the 30-day
period prior to vesting. Additional option shares will be granted for the
difference if the market price is below $0.40 during the 30-day period.
The Black-Scholes option pricing model was used to determine the fair value of
the option guarantee issued to CrownBeav with the following assumptions:
risk free interest rate of 4.60%; dividend yield of 0%; volatility factors of
100%, the expected market price of the Companys common shares over the
guarantee period of 2 years. The resulting fair value of the put option
was $185,000. The $526,726 fair market value of the option (combination
of call and put) was capitalized as an intangible asset and is being recognized
as a licensing fee over the 10 year period of the license.
On
October 24, 2007, the Company entered into a one year Authorized Detailer
Agreement with Sheervision, Inc. (Sheervision), a Delaware corporation,
under which the Company became an authorized broker and detailer of Sheervisions
Firefly Infinity LED Headlight and all related accessories. The agreement will be renewed for an
additional one or two year period in 2008.
The Company was appointed as an exclusive authorized detailer in certain
international markets and as a non-exclusive authorized detailer in Sheervisions
retained territory, excluding the United States of America. In consideration of the Companys efforts to
develop and retain an international dealer network, Sheervision will pay the
Company a monthly management fee during the first four months of the agreement
and a commission for all products sold in the AMT managed territory during the
agreement period.
On
March 20, 2008 the Company entered into a three year Authorized Detailer
Agreement with DentNCo, a French company, under which the Company became an
authorized broker and detailer of DentNCos Flexiwhite Tooth Whitening Light
and related accessories. The Company was
appointed as an exclusive authorized detailer in certain international
markets. In consideration of the Companys
efforts to develop and retain an international dealer network, DentNCo will
pay the Company monthly commission for all products sold in the AMT managed
territory during the agreement period.
The
Company has suffered recurring losses from operations, and its total
liabilities exceed its total assets. This raises substantial doubt about the
Companys ability to continue as a going concern. The Companys ability to
generate positive operational cash flow is dependent upon increasing revenues
through the sales of existing product lines and the expansion related to the
representation of additional lines of dental products. While the Company
has identified additional product lines and has ongoing dialogs with dental
product manufacturers, there can be no assurance that the Company will be
successful in finalizing the contract for representation of these products or
that the Company will be successful in generating a positive operational cash
flow.
16
ITEM 3
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
None
required.
ITEM 4T
CONTROLS AND PROCEDURES
The
Companys management, with the participation of the chief executive officer and
principal accounting officer, evaluated the effectiveness of our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15
under the Exchange Act) as of March 31, 2008. Based upon this evaluation, the chief
executive officer and principal accounting officer concluded that the Companys
disclosure controls and procedures were effective. Subsequent to the evaluation and through the
date of this filing of Form 10-Q for the three month period ended March 31,
2008, there have been no significant changes in the Companys internal controls
over financial reporting (as defined in Rules 13a-15(f) and 15-d-15(f) under
the Exchange Act) or in any other factors that could significantly affect these
controls.
PART II
OTHER INFORMATION
ITEM 1
LEGAL PROCEEDINGS
In
the normal course of business, we may become involved in various legal
proceedings. As of March 31, 2008, we know of no pending or
threatened legal proceeding to which we are or will be a party which, if
successful, might result in material adverse change in our business properties
or financial condition. However, as with most businesses, we are
occasionally parties to lawsuits incidental to our business, none of which are
anticipated to have a material adverse impact on our financial position, results
of operations, liquidity or cash flows. We estimate the amount of
potential exposure it may have with respect to litigation claims and
assessments.
ITEM 1A
RISK FACTORS
Not
required
ITEM 2
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None
ITEM 3
DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM 5
OTHER INFORMATION
None
ITEM 6
EXHIBITS
17
Exhibit Index
3.1
|
|
Second
Restated Certificate of Incorporation (Form 10-Q for the quarter ended
September 30, 2002)
|
|
|
|
3.2
|
|
Certificate
of Correction to the Second Restated Certificate of Incorporation
(Form 10-K for year ended December 31, 2002.)
|
|
|
|
3.3
|
|
Certificate
of Designation of Series B Preferred Stock (Form 10-K for year
ended December 31, 2002.)
|
|
|
|
3.4
|
|
Certificate
of Amendment to the Second Amended and Restated Certificate of Incorporation
dated May 12, 2005 (Form 10-Q for the quarter ended June 30,
2005)
|
|
|
|
4.1
|
|
Amendment
Agreement with Aimee Maroney effective as of June 17, 2003
(Form 10-Q for quarter ended June 30, 2003)
|
|
|
|
4.2
|
|
Agreement
to Assign Lien and Release Claims with Aimee Maroney and Value Bank Texas
dated as of June 17, 2003 (Form 10-Q for quarter ended June 30,
2003)
|
|
|
|
4.3
|
|
Promissory
Note issued to Texas State Bank dated February 9, 2005 (Form 10-K
for year ended December 31, 2004)
|
|
|
|
4.4
|
|
Deed
of Trust granted to Paul S. Moxley, Trustee for Texas State Bank, dated
February 9, 2005 (Form 10-K for year ended December 31, 2004)
|
|
|
|
4.5
|
|
Stock
Purchase Warrant dated April 11, 2006 for 2,300,000 shares issued to
Discus Holdings, Inc. (Form 10-KSB for year ended December 31,
2005)
|
|
|
|
4.6
|
|
Put
and Call Option Agreement dated April 11, 2006 between Discus Holdings, Inc.
and American Medical Technologies, Inc. (Form 10-KSB for year ended
December 31, 2005)
|
|
|
|
4.7
|
|
Registration
Rights Agreement dated April 11, 2006 between American Medical
Technologies, Inc. and Discus Holdings, Inc. (Form 10-KSB for
year ended December 31, 2005)
|
|
|
|
10.1
|
|
Amended
and Restated Nonqualified Stock Option Plan (Registration No. 33-40140)
|
|
|
|
10.2
|
|
Stock
Option Plan for Employees (Registration No. 33-40140)
|
|
|
|
10.3
|
|
Amended
and Restated Long-Term Incentive Plan (Form 10-Q for quarter ended
September 30, 1996)
|
|
|
|
10.4
|
|
American
Medical Technologies, Inc. 2005 Stock Option Plan (Form 10-Q for
the quarter ended June 30, 2005)
|
|
|
|
10.5
|
|
License
Agreement between Texas Airsonics, Inc., a wholly owned subsidiary of
American Medical Technologies, Inc. and Texas Airsonics, L.P.
(Form 10-K for year ended December 31, 1996)
|
|
|
|
10.5
|
|
Patent
License Agreement dated October 18, 1997 between Danville
Engineering, Inc. and American Medical Technologies, Inc.
(Form 10-Q for quarter ended September 30, 1997)
|
|
|
|
10.7
|
|
Assignment
from Sunrise Technologies International, Inc. to Lares Research dated
June 24, 1997 (Form 10-K for year ended December 31, 1997)
|
|
|
|
10.8
|
|
Patent
License Agreement dated June 29, 1998 Prep-Technology Corp. and American
Medical Technologies, Inc. (Form 10-Q for quarter ended
June 30, 1998)
|
|
|
|
10.9
|
|
Patent
License Agreement dated as of January 21, 1999 between ESC Medical
Systems, Ltd. and American Medical Technologies, Inc. (Form 10-Q
for quarter ended March 31, 1999)
|
18
10.10
|
|
Patent
licensing Agreement dated June 10, 1999 between American Medical
Technologies, Inc. and Kreativ, Inc. (Form 10-Q for quarter
ended June 30, 1999)
|
|
|
|
10.11
|
|
Employment
Agreement dated effective as of June 1, 2004, between American Medical
Technologies, Inc. and Roger W. Dartt (Form 10-Q for the quarter
ended September 30, 2004)
|
|
|
|
10.12
|
|
Exclusive
License Agreement dated April 11, 2006 between Discus
Holdings, Inc., Spectrum Dental, Inc. and American Medical
Technologies, Inc. (Form 10-KSB for year ended December 31,
2005)
|
|
|
|
10.13
|
|
Manufacturing
Agreement dated April 11, 2006 between Westside Packaging, Inc. and
American Medical Technologies, Inc. (Form 10-KSB for year ended
December 31, 2005)
|
|
|
|
10.14
|
|
Commercial
Contract Improved Realty dated April 11, 2006 between American Medical
Technologies, Inc. and The Sepulveda Group, LLC (Form 10-KSB for
year ended December 31, 2005)
|
|
|
|
10.15
|
|
Lease
dated April 11, 2006 between The Sepulveda Group, LLC and American
Medical Technologies, Inc. (Form 10-KSB for year ended
December 31, 2005)
|
|
|
|
10.16
|
|
Standstill
Agreement dated February 1, 2007
|
|
|
|
10.17
|
|
First
Amendment to the Put and Call Option Agreement dated April 10, 2007
|
|
|
|
10.18
|
|
Employment
Agreement dated effective as of January 1, 2007, between American
Medical Technologies, Inc. and Judd D. Hoffman
|
|
|
|
21
|
|
Subsidiaries
of the Registrant (Form 10-K for year ended December 31, 1999)
|
|
|
|
31.1*
|
|
Certification
of Judd D. Hoffman, President and Chief Executive Officer of the Company, as
required by Rule 13a-14(a).
|
|
|
|
31.2*
|
|
Certification
of Barbara Woody, principal accounting officer of the Company, as required by
Rule 13a-14(a).
|
|
|
|
32*
|
|
Certification
of Chief Executive Officer and of principal accounting officer of the
Company, as required by 18 U.S.C. Section 1350.
|
*
Filed herewith
19
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
American
Medical Technologies, Inc.
|
|
|
|
|
|
|
Date: May 15,
2008
|
|
/s/
Judd D. Hoffman
|
|
|
Judd
D. Hoffman
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
|
|
Date: May 15,
2008
|
|
/s/
Barbara Woody
|
|
|
Barbara
Woody
|
|
|
Vice
President of Administration and Finance, and
principal accounting officer
|
20
American Medical Technol... (CE) (USOTC:ADLI)
Historical Stock Chart
From Nov 2024 to Dec 2024
American Medical Technol... (CE) (USOTC:ADLI)
Historical Stock Chart
From Dec 2023 to Dec 2024